GlobeNews Wire

Aveanna Announces Pricing of Secondary Offering of Common Stock

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused…

6 months ago

Biomea Fusion to Participate in Citi’s SMID Biotech C-Suite Fireside Chat Series

October 21, 2025 19:05 ET  | Source: Biomea Fusion, Inc. SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea…

6 months ago

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization…

6 months ago

IDI Announces Integration with TazWorks to Expand Access to IDIs Best-in-Class Identity Intelligence in the Background Screening Industry

October 21, 2025 12:21 ET  | Source: Interactive Data, LLC BOCA RATON, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Interactive…

6 months ago

Youxin Technology Ltd Regains Compliance with Nasdaq Listing Requirements

GUANGZHOU, CHINA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (Nasdaq: YAAS) (the “Company” or “Youxin Technology”), a software…

6 months ago

Inveniam and Mantra unveil Inveniam Chain: A layer 2 blockchain for private real estate assets

ABU DHABI, United Arab Emirates and DUBAI, United Arab Emirates and NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inveniam…

6 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…

6 months ago

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…

6 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Companys Ongoing Transformation

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable…

6 months ago

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

6 months ago